Sofinnova Investments’s Neurocrine Biosciences NBIX Stock Holding History

Sofinnova Investments’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-203,200	Closed	-$19.8M	–	81
2021 Q2	$19.8M	Buy	+203,200	New	+$19.5M	1.14%	24
2019 Q4	–	Sell	-191,679	Closed	-$17.3M	–	66
2019 Q3	$17.3M	Buy	191,679 +35,819	+23%	+$3.35M	1.56%	19
2019 Q2	$13.2M	Buy	155,860 +43,454	+39%	+$3.57M	1.21%	18
2019 Q1	$9.9M	Buy	112,406 +50,906	+83%	+$4.25M	0.95%	22
2018 Q4	$4.39M	Buy	+61,500	New	+$5.89M	0.55%	35

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

EVM

Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return

Sofinnova Investments's NBIX Position: Q3 2021 in Review

Sofinnova Investments sold out of Neurocrine Biosciences (NBIX) in Q3 2021, closing a stake of 203,200 shares — an estimated $19.8M sold.

Sofinnova Investments first reported a position in NBIX in Q4 2018 and held it in 5 quarters. The position peaked at $19.8M in Q2 2021. 395 funds tracked by Wall St. Rank hold NBIX as of Q3 2021.

Sofinnova Investments reported no remaining Neurocrine Biosciences position as of Q3 2021 after selling out during the quarter.
Sofinnova Investments sold 203,200 Neurocrine Biosciences shares in Q3 2021, an estimated $19.8M.
Sofinnova Investments first reported a position in Neurocrine Biosciences in Q4 2018 and held it in 5 quarters.
Sofinnova Investments's Neurocrine Biosciences position peaked at $19.8M in Q2 2021.
395 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2021.

Based on Sofinnova Investments's 13F filing for Q3 2021, filed 15 Nov 2021.